A Study Of Early Markers Of Choroidal Neovascularization
A Two-Year Exploratory, Observational, Non-Interventional Multicenter Study To Identify Early Markers Of Choroidal Neovascularization In Fellow Eyes Of Patients With Neovascular AMD In One Eye
Sponsor: Pfizer
Terminated
This trial was terminated. No reason was provided.
Other terminated trials from Pfizer
Other Age-related Macular Degeneration (AMD) trials with similar outcome
A observational or N/A phase clinical study on Age-related Macular Degeneration (AMD) and Choroidal Neovascularization (CNV), this trial is terminated or withdrawn. The trial is conducted by Pfizer and has accumulated 7 data snapshots since 2008. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Terminated
-
Sep 2024 — Sep 2025 [monthly]
Terminated
-
Jul 2024 — Sep 2024 [monthly]
Terminated
-
Jan 2021 — Jul 2024 [monthly]
Terminated
-
Jun 2018 — Jan 2021 [monthly]
Terminated
▶ Show 2 earlier versions
-
Apr 2018 — Jun 2018 [monthly]
Terminated
Phase: PHASE4 → None
-
Jan 2017 — Apr 2018 [monthly]
Terminated PHASE4
First recorded
Mar 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Pfizer
For direct contact, visit the study record on ClinicalTrials.gov .